CD52 Antigen

"CD52 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A small GPI-linked glycoprotein expressed on the surface of normal and malignant B-CELLS; T-CELLS; MONOCYTES; MACROPHAGES; NK CELLS; and GRANULOCYTES. It is expressed densely and without modulation in many malignant T-cell neoplasms and therefore a target for antibody therapies (e.g., ALEMTUZUMAB).

Descriptor ID	D000074301
MeSH Number(s)	D12.776.395.550.448.190 D12.776.543.484.500.190 D12.776.543.550.418.190 D23.050.285.022 D23.101.100.943
Concept/Terms	CD52 Antigen CD52 Antigen CDw52 Antigen Campath-1 Antigen Campath 1 Antigen Campath-1H Antigen Campath 1H Antigen Lymphocyte Antigen CDw52 CDw52, Lymphocyte Antigen Lymphocyte Antigen CD52 CD52, Lymphocyte Antigen Campath-1 Receptor Campath 1 Receptor HLA-Bw52 Antigen HLA Bw52 Antigen HLA-Bw52 HLA Bw52 Cambridge Pathology 1 Antigen CD52 Protein

Below are MeSH descriptors whose meaning is more general than "CD52 Antigen".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Glycoproteins [D12.776.395]
Membrane Glycoproteins [D12.776.395.550]
GPI-Linked Proteins [D12.776.395.550.448]
CD52 Antigen [D12.776.395.550.448.190]
Membrane Proteins [D12.776.543]
Lipid-Linked Proteins [D12.776.543.484]
GPI-Linked Proteins [D12.776.543.484.500]
CD52 Antigen [D12.776.543.484.500.190]
Membrane Glycoproteins [D12.776.543.550]
GPI-Linked Proteins [D12.776.543.550.418]
CD52 Antigen [D12.776.543.550.418.190]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Neoplasm [D23.050.285]
CD52 Antigen [D23.050.285.022]
Biomarkers [D23.101]
Antigens, Differentiation [D23.101.100]
CD52 Antigen [D23.101.100.943]

Below are MeSH descriptors whose meaning is related to "CD52 Antigen".

Below are MeSH descriptors whose meaning is more specific than "CD52 Antigen".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "CD52 Antigen" by people in this website by year, and whether "CD52 Antigen" was a major or minor topic of these publications.

Bar chart showing 7 publications over 6 distinct years, with a maximum of 2 publications in 2003

To see the data from this visualization as text, click here.

Year	Minor Topic	Total
2002	1	1
2003	2	2
2004	1	1
2005	1	1
2006	1	1
2013	1	1

Below are the most recent publications written about "CD52 Antigen" by people in Profiles.

Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, Zhu H, Markovic-Plese S. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013 Dec 15; 191(12):5867-74.

View in: PubMed
Magro CM, Morrison CD, Heerema N, Porcu P, Sroa N, Deng AC. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism. J Am Acad Dermatol. 2006 Sep; 55(3):467-77.

View in: PubMed
Mone A, Puhalla S, Whitman S, Baiocchi RA, Cruz J, Vukosavljevic T, Banks A, Eisenbeis CF, Byrd JC, Caligiuri MA, Porcu P. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia. Blood. 2005 Nov 15; 106(10):3380-2.

View in: PubMed
Snyder MJ, Stenzel TT, Buckley PJ, Lagoo AS, Rizzieri DA, Gasparetto C, Vredenburgh JJ, Chao NJ, Gong JZ. Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol. 2004 Jun; 28(6):794-800.

View in: PubMed
Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. 2003 Oct 01; 63(19):6453-7.

View in: PubMed
Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 01; 101(9):3413-5.

View in: PubMed
Bass AJ, Gong J, Nelson R, Rizzieri DA. CD52 expression in mantle cell lymphoma. Leuk Lymphoma. 2002 Feb; 43(2):339-42.

View in: PubMed
Friend PJ, Rebello P, Oliveira D, Manna V, Cobbold SP, Hale G, Jamieson NV, Jamieson I, Calne RY, Harris DT, et al. Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody. Transplant Proc. 1995 Feb; 27(1):869-70.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement